Navigation Links
Delcath Submits New Drug Application For Proprietary Chemosaturation System To The U.S. Food And Drug Administration
Date:8/15/2012

NEW YORK, Aug. 15, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for the Company's proprietary chemosaturation system for use with melphalan hydrochloride in the treatment of patients with unresectable metastatic melanoma in the liver. The Company included its Generation 2 filter in its NDA submission as a technical change to the Chemistry, Manufacturing, and Control (CMC) module.

"Our team has achieved a significant milestone with the filing of our NDA," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "We believe that our chemosaturation system provides the opportunity to satisfy a high unmet medical need to treat patients with unresectable metastatic melanoma in the liver. We also believe including our Generation 2 filter in the CMC module represents the fastest regulatory review path for the Generation 2 system, and that it is in the best interest of U.S. patients that we accelerate the potential availability of Generation 2."

"We have requested priority review of our NDA by the FDA. Assuming the NDA is accepted and that priority review is granted, our expected Prescription Drug User Fee Act (PDUFA) date would be in February of next year.  Based upon the strength of our Phase 1, 2 and 3 data, along with the limited treatment options available for patients with unresectable melanoma metastases in the liver, we believe that our application meets the FDA's criteria for priority review."

In Delcath's Phase 3 clinical trial (April 2010 data cutoff), comparing treatment with the Company's proprietary chemosaturation system to best alternative care (BAC) revealed that patients treated with chemosaturation therapy experienced a statistically significant extension in median hepatic progression free survival (hPFS) o
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Systems, Inc. Secures $20 Million Credit Facility
2. Delcath Highlights First Quarter 2012 And Recent Accomplishments
3. Delcath to Webcast Managements Presentation at Annual Meeting of Stockholders
4. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
5. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
6. Delcath Announced Changes To Board Of Directors
7. Delcath To Present At JMP Securities Healthcare Conference On July 12
8. Delcath To Conduct Second Quarter 2012 Results Conference Call
9. Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments
10. Delcath To Present At Upcoming Investor Conferences
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Electrodes are devices that convert ... amplified to diagnose as well as treat several ... devices facilitate the detection of chemical reactions derived ... neurons of the patients. In addition, few electrodes ... current to perform minimally invasive surgical procedures. The ...
(Date:10/30/2014)... Oct. 29, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... months ended September 30, 2014. "During ... at the beginning of 2014 by securing a partner to ... expanding the market into countries where we do not have ... We believe this partnership will maximize the value of PIXUVRI ...
(Date:10/30/2014)... NEW YORK , Oct. 29, 2014 /PRNewswire/ ... strong growth through 2013 with the introduction of ... are well-covered in Vaccines: The World Market. The ... vaccines, covering specifically commercialized vaccines and developmental vaccines ... protects not only individuals, but also entire communities ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... , , MOUNTAIN VIEW, Calif., Dec. 16 ... patients in a Phase 2 clinical trial of CCX354, an ... CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA). ... of CCR1, a chemokine receptor that drives the recruitment of ...
... , , ... - Studies Conducted at INRA-Agroparistech Laboratory Under Pr. Daniel,Tome,s Supervision ... International Bone and Mineral Society "Bone", Reveal new Benefits for,Peptan(TM) ... to consumer concerns regarding long-term bone health,Rousselot has carried out, ...
Cached Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health 2
(Date:10/30/2014)... CA (PRWEB) October 30, 2014 Graphics, ... terms are synonymous with the craft of web design ... functional website. Yet a simpler solution to create a ... Thus, pictures, videos, contact information, customer reviews and Facebook ... , "It is the next evolution of how ...
(Date:10/30/2014)... 30, 2014 High efficacy and ... in the medical-grade skin care domain: Cosmederm, the ... uniquely potent topical dermatological products, today announces the ... ) with patented COSMEDERM®-7 anti-irritant technology. , ... (50% and 70%) and a low pH (pH ...
(Date:10/30/2014)... 2014 PreDiabetes Centers , the ... shoppers with a supply of sugardown®, a chewable ... post-meal blood sugar spikes. Learning how to control blood ... part of a diabetes prevention plan. , Shoppers who ... complimentary tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
(Date:10/30/2014)... Tara Haelle HealthDay Reporter ... More than 100 genes have been identified that appear ... And researchers say they are on their way ... contribute to the disorder. Autism spectrum disorders include ... social difficulties and repetitive behaviors. An estimated one in ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... computed tomography (CT), magnetic resonance imaging and molecular imaging ... multi-modal contrast agent – Researchers // at the University ... these new agents may, in turn, significantly improve the ... a professor in the department of speech and hearing ...
... In the race for supremacy in the Indian biotech ... spot during the fiscal (2005-06) // by contributing ... (Rs.65 billion) as against 37 percent by the southern ... performance, Karnataka Biotech Vision group chairperson Kiran Mazumdar-Shaw told ...
... has been develooped to assess the risk of heart disease ... wrongly assessed. // ,ETHRISK is for everyday use ... has been developed by researchers at the University of Bristol ... British black and minority ethnic groups. ,Ethnic groups within Britain ...
... African union and aid organisations said on Wednesday, that, Africa ... years. // This is about three times as much as the ... pledge, in Beijing, made at a donors conference did not expect ... been reported in eight African countries since February, and this ...
... revealed that while the chances of surviving a heart attack ... unchanged. // ,The Canadian Institute for Health Information ... rate for people suffering a new heart attack fell to ... 1999-2000 whereas in the case of strokes, 18.8 per cent ...
... According to the recent report from the health authorities of central ... disease//. Statistics show that the disease is prevalent in the month ... ,The scenario was worse in 2002 were human deaths crossed 66. ... by the health authorities the number of deaths reduced to 12 ...
Cached Medicine News:Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 2Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 3Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 4Health News:Western Region Tops in Indian Biotech Growth 2Health News:New Web- Based Calculator to Assess Heart Disease Risk 2Health News:Survival Rates of Heart Attack Improving 2
... manual hemostasis analyzer that is ideal ... PTs, aPTTs, thrombins, fibrinogens and factor ... testing, this analyzer is small in ... time and labor saving benefits. Operation ...
... STart benchtop coagulation analyzers feature ... clot detection. This method eliminates ... other optically dense samples or ... and preprogrammed assays with curve ...
... Description,The STA-R Evolution is a fully-automated, ... the total laboratory automation line. Clotting, ... simultaneously in random access mode. The ... offers high throughput and rapid processing ...
The ACL 9000 together with an extensive test menu and superior technology is backed by high-quality service to keep the lab running efficiently....
Medicine Products: